Amivantamab is indicated for:
Population group: both men and women, only adults (18 years old or older)
Amivantamab as monotherapy is indicated for treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):